Laryngeal cancer has become the focus of research because of its high incidence rate and mortality rate. However, the research on miR-194-5p in laryngeal cancer is quite rare. The purpose of this study is to explore the effect of miR-194-5p on the proliferation and invasion of laryngeal cancer cells in order to find an effective way to treat laryngeal cancer. The results showed that miR-194-5p could activate the mTOR signaling pathway by regulating the expression of Smurf1, which had an effect on laryngeal cancer cells. The results showed that the absorbance of the miR-194-5p group was 0.38 lower than that of the NC group, which indicated that up-regulation of mir-194-5p could weaken the proliferation of laryngeal cancer cells. In addition, the average number of laryngeal cancer cells in NC and the miR-194-5p groups was 125.2 and 53.8, respectively, which indicated that miR-194-5p could reduce the number of laryngeal cancer cells passing through the basement membrane and their invasion ability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14715/cmb/2022.68.6.13 | DOI Listing |
Ther Adv Med Oncol
January 2025
Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089 Rozzano, Italy.
Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC.
View Article and Find Full Text PDFClin Otolaryngol
January 2025
School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.
Objectives: This descriptive epidemiological study aims to investigate trends in head and neck cancer (HNC) within the anatomical divisions of laryngeal, oropharyngeal, and oral cavity cancers over the past two decades.
Design: Retrospective population-based observational study.
Setting: Scotland, a constituent country of the United Kingdom, with a population of 5.
Auris Nasus Larynx
January 2025
Department of Otolaryngology Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama 700-8558, Japan.
Objective: An optimal surgical approach for intermediate-risk papillary thyroid cancer (PTC) has not yet been established. The surgical procedure should be determined based on treatment outcomes and postoperative complications. This study aimed to evaluate appropriate surgical strategies for patients with intermediate-risk PTC by comparing treatment outcomes and postoperative complications following total thyroidectomy and lobectomy.
View Article and Find Full Text PDFAuris Nasus Larynx
January 2025
Department of Otolaryngology-Head and Neck Surgery, Nara Medical University.
Objective: Epidemiological surveys were conducted in Nara Prefecture, Japan, to determine the prevalence of head and neck cancer in the region since 1986.
Methods: This study examined the dynamics of visits to 18 medical institutions treating head and neck cancer in Nara Prefecture from 2000 to 2021.
Results: A total of 8,605 patients were registered, with 4,788 being male and 3,787 female.
Laryngoscope
January 2025
Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, Louisiana, U.S.A.
Objective: To identify the most effective treatment modality for achieving favorable outcomes in early glottic tumors with anterior commissure involvement (ACI).
Data Sources: PubMed, Embase, Web of Science, and ScienceDirect.
Review Methods: Random-effects proportional meta-analysis model is used to evaluate the oncological and functional outcomes of transoral laser microsurgery (TLM) versus radiation therapy (RT) in early glottic (T1-T2) cancer with ACI.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!